

Electronic Supporting Information



Influence of the reducing-end anomeric configuration of the Man₉ epitope on DC-SIGN recognition.

Noelia de la Cruz,^a Javier Ramos-Soriano,^{a*} José J. Reina,^a José L. de Paz,^a Michel Thépaut,^b Franck Fieschi,^b Ana Sousa-Herves^a and Javier Rojo^{a*}


- a) Glycosystems Laboratory, Instituto de Investigaciones Químicas (IIQ), CSIC - Universidad de Sevilla, Av. Américo Vespucio 49, Seville 41092, Spain. E-mail: javiramossoriano@gmail.com; javier.rojo@iiq.csic.es; b) Univ. Grenoble Alpes, CNRS, CEA, Institut de Biologie Structurale, 38000 Grenoble, France

¹H and ¹³C NMR spectra and selected HSQC and MS spectra


Compound 6



Compound 9




¹H-NMR (400 MHz, CDCl₃): compound 9.




¹³C-NMR (100 MHz, CDCl₃): compound 9.

Compound 10




¹H-NMR (400 MHz, CDCl₃): compound **10**.




¹³C-NMR (100 MHz, CDCl₃): compound **10**.


Compound 11



^1H -NMR (400 MHz, CDCl_3): compound **11**.




^{13}C -NMR (100 MHz, CDCl_3): compound **11**.




ESI-MS: compound **11**.


Compound 12



^1H -NMR (400 MHz, D_2O): compound **12**.




^{13}C -NMR (100 MHz, D_2O): compound **12**.




ESI-MS: compound **12**.

Compound 15






^1H -NMR (400 MHz, D_2O): compound **15**.





^{13}C -NMR (100 MHz, D_2O): compound **15**.

Compound 16








Compound 17






^1H -NMR (400 MHz, D_2O): compound **17**.




Compound 18







Compound 20



^1H -NMR (400 MHz, D_2O): compound 20.




HSQC-NMR (D_2O): compound 20.




ESI-MS: compound 20.

Compound 21





^1H -NMR (400 MHz, D_2O): compound **21**.

HSQC-NMR (D_2O): compound **21**.




ESI-MS: compound **21**.


Compound 22



^1H -NMR (400 MHz, D_2O): compound 22.




HSQC-NMR (D_2O): compound 22.




ESI-MS: compound **22**.


Compound **23**



¹H-NMR (400 MHz, D₂O): compound **23**.



HSQC-NMR (D₂O): compound **23**.



ESI-MS: compound **23**.

Protocol for DC-SIGN ECD purification

DC-SIGN ECD sample, used for this work, was purified using a routine 2 steps automated protocol on Akta Xpress derived from the reference J Biol Chem 2009, 284, 21229-40 (<https://pubmed.ncbi.nlm.nih.gov/19502234/>), in which we demonstrated that DC-SIGN ECD is a tetramer. A Mannan-Agarose column to ensure its functionality, eluted with EDTA and after a Superose12 column to ensure its homogeneity, reload the carbohydrate recognition site with Ca and to remove aggregates.

Chromatogram of the automated protocol for purification:

- loading of Mannan-Agarose column.
- washing of Mannan-Agarose column.
- elution of Mannan-Agarose column, with peak at ~1300 mAU, which was loaded into a storage loop and reinjected in fractions of 2mL on gel filtration.
- 4 cycles of gel filtration with injection of 2 mL of sample coming from storage loop.

2018.01.22.DC.SIGN.ECD.purification.new001:10_UV
 2018.01.22.DC.SIGN.ECD.purification.new001:10_Cond
 2018.01.22.DC.SIGN.ECD.purification.new001:10_Fractions
 2018.01.22.DC.SIGN.ECD.purification.new001:10_Inject
 2018.01.22.DC.SIGN.ECD.purification.new001:10_Logbook

